ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary ...(ocolitiscaused by Staphylococcus aureus ...),Health

Date:11/12/2008

ocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's clinical development programs. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were presented at the ACAAI Annual Meeting regarding the in the ongoing open-label study of Cinryze for acute treatment of HAE is partial data from an ongoing open label study. There can be no assurance that the complete data from this study will demonstrate that Cinryze successfully treats all types of acute hereditary angioedema (HAE) attacks and may not be predictive
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test